Fritextsökning
Innehållstyper
-
A mass flow controller that is silent, fast and cost-effective
Portable ventilator breathing devices, bioreactors or the dosing of inert gases all rely on the highest control dynamics. That is exactly what the proportional ...
-
Advancing Drug Discovery by Combining Complex In-Vitro Models with AI-Powered 3D/4D Image Analysis
Free webinar organized by ZEISS.
-
On the hunt for high throughput diagnostics
Global diagnostics companies and laboratories are in a race against time to adapt testing capacity to current demand. Due to the global COVID 19 pandemic, the d...
-
FDA approves new cystic fibrosis therapy
A new treatment for cystic fibrosis has been approved by the U.S. Food and Drug Administration (FDA).
-
Jan Holmgren to receive award for the development of cholera vaccine
Researcher Jan Holmgren is being awarded for the development of the first effective drinkable cholera vaccine. The award is given by the International Vaccine I...
-
Your solution for right part positioning
ZEISS OmniFix CT - right part positioning solution to get meaningful measuring results for all part sizes.
-
Partial court victory for entrepreneur who lost his company
Swedish life science entrepreneur Mikael Kubista has won the first round against a law firm that he, along with other co-owners, sued for negligent advice in co...
-
How to optimise your liquid handling results
In dispensing or pipetting applications in laboratory automation, it is important to obtain reliable results, which are analysed by calculating the accuracy and...
-
ZEISS announces CE mark for CIRRUS PathFinder AI tool with automated OCT assessment
Fully integrated AI decision support tool flags B scans that may require further review, supporting more confident decision making and more efficient patient care.
-
EMA review confirms a risk of new cancer after CAR-T
CAR-T cancer therapies can, in rare cases, induce secondary cancers. The European Medicines Agency (EMA) now recognises this and requires a warning label to be ...
-
Introducing ZEISS arivis Pro 4.2
ZEISS arivis software enhances custom microscopy image analysis.
-
Settlement of cancer allegations against blockbuster drug
French pharmaceutical company Sanofi has reached a principal agreement in the US on around 4,000 of the cases in which its now withdrawn blockbuster heartburn d...
-
Forskaren in Hagastaden now inagurated
The real estate company Vectura's life science center in Hagastaden, Forskaren, is now inaugurated. The opening was attended by people from the industry, politi...
-
“Don’t postpone the transition to IVDR”
Operators who have not yet started to adapt to the requirements of the new EU IVDR regulation are running out of excuses. This is the opinion of Helena Dzojic, ...
-
The physician at the tech giant: “Observations in the emergency room made my mind up”
When Nasim Farrokhnia was in third grade at school in Tehran, the capital of Iran, her father gave her a book about Marie Curie, which soon became her favourite...
-
Standardisation in automation
B. Braun Melsungen had a great idea and implemented it throughout the plant. Production for infusion solutions was to be largely standardised. B. Braun hoped th...
-
Bio Europe to Stockholm – ”The Swedish ecosystem is now taking the opportunity”
The international life science conference Bio Europe is coming to Sweden for the first time in November. The conference, whose program takes inspiration from AB...
-
Nytt samarbete: Chat GPT flyttar in i Lundbecks laboratorier
Den danska läkemedelskoncernen Lundbeck tar hjälp av Open AI för att påskynda forskning och effektivisera arbetet inom hela verksamheten.
-
The future of healthcare in focus: ”Together, things happen”
In march, it’s once again time for Fokus Patient, an event for the industry where the patients’ perspective takes center stage. It’s a great way to spread knowl...
-
KI’s freezer fiasco investigated: A chain of failures
A chain of combined technical and organisational shortcomings caused the freezer breakdown at the Karolinska Institute during the Christmas holidays, destroying...
-
Positive EMA Decision for BioArctic's New Drug Candidate
Bioarctic's drug candidate for multiple system atrophy, exidavnemab, is recommended to be classified as an orphan drug, according to the European Medicines Agency (EMA).
-
Study names with an attitude – more important than you might think
Ironman, T-rex, Star-Trek. Popcorn, Proper, Scout. Nope, these are neither fantasy films nor dog names. They’re the names of ongoing cancer studies in Sweden.
-
He takes over the chairmanship of Karolinska Development
Ben Toogood is appointed as the new chairman of Karolinska Developments.
-
Smartzoom 100 – The New Digital Microscope for Maximum Efficiency
Free webinar July 1, 9:00-9:45 AM CEST and 5:00-5:45 PM CEST.
BREAKING